Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial.

Mannelli P, Patkar AA, Peindl K, Gorelick DA, Wu LT, Gottheil E.

Addict Biol. 2009 Apr;14(2):204-13. doi: 10.1111/j.1369-1600.2008.00119.x. Epub 2008 Aug 19.

2.

Problem drinking and low-dose naltrexone-assisted opioid detoxification.

Mannelli P, Peindl K, Patkar AA, Wu LT, Tharwani HM, Gorelick DA.

J Stud Alcohol Drugs. 2011 May;72(3):507-13.

3.

The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.

Mannelli P, Peindl K, Wu LT, Patkar AA, Gorelick DA.

Am J Drug Alcohol Abuse. 2012 May;38(3):200-5. doi: 10.3109/00952990.2011.644003. Epub 2012 Jan 10.

4.

Early outcomes following low dose naltrexone enhancement of opioid detoxification.

Mannelli P, Patkar AA, Peindl K, Gottheil E, Wu LT, Gorelick DA.

Am J Addict. 2009 Mar-Apr;18(2):109-16. doi: 10.1080/10550490902772785.

5.

Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.

Mannelli P, Wu LT, Peindl KS, Swartz MS, Woody GE.

Drug Alcohol Depend. 2014 May 1;138:83-8. doi: 10.1016/j.drugalcdep.2014.02.002. Epub 2014 Feb 15.

6.

The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.

Bisaga A, Sullivan MA, Glass A, Mishlen K, Pavlicova M, Haney M, Raby WN, Levin FR, Carpenter KM, Mariani JJ, Nunes EV.

Drug Alcohol Depend. 2015 Sep 1;154:38-45. doi: 10.1016/j.drugalcdep.2015.05.013. Epub 2015 Jul 8.

7.

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL.

Lancet. 2011 Apr 30;377(9776):1506-13. doi: 10.1016/S0140-6736(11)60358-9.

PMID:
21529928
8.

Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Sigmon SC, Bisaga A, Nunes EV, O'Connor PG, Kosten T, Woody G.

Am J Drug Alcohol Abuse. 2012 May;38(3):187-99. doi: 10.3109/00952990.2011.653426. Epub 2012 Mar 12. Review.

9.

Use of very low-dose naltrexone during opiate detoxification.

Mannelli P, Gottheil E, Buonanno A, De Risio S.

J Addict Dis. 2003;22(2):63-70.

PMID:
12703669
10.
11.

Three methods of opioid detoxification in a primary care setting. A randomized trial.

O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ.

Ann Intern Med. 1997 Oct 1;127(7):526-30.

PMID:
9313020
12.
13.

Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.

Mannelli P, Patkar AA, Peindl K, Murray HW, Wu LT, Hubbard R.

J Clin Psychopharmacol. 2007 Oct;27(5):468-74.

PMID:
17873678
14.

Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Mannelli P, Peindl KS, Lee T, Bhatia KS, Wu LT.

Curr Drug Abuse Rev. 2012 Mar;5(1):52-63. Review.

15.

Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial.

Yuan CS, Foss JF, O'Connor M, Osinski J, Karrison T, Moss J, Roizen MF.

JAMA. 2000 Jan 19;283(3):367-72.

PMID:
10647800
16.

[Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].

Krupitski─ş EM, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Blokhina EA, Silverman BL.

Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(5 Pt 2):3-11. Russian.

PMID:
22951790
17.

A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.

Bisaga A, Sullivan MA, Glass A, Mishlen K, Carpenter KM, Mariani JJ, Levin FR, Nunes EV.

J Subst Abuse Treat. 2014 May-Jun;46(5):546-52. doi: 10.1016/j.jsat.2014.01.005. Epub 2014 Jan 17.

18.
19.

Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?

Nunes EV, Krupitsky E, Ling W, Zummo J, Memisoglu A, Silverman BL, Gastfriend DR.

J Addict Med. 2015 May-Jun;9(3):238-43. doi: 10.1097/ADM.0000000000000125.

20.

Opioid dependence treatment: options in pharmacotherapy.

Stotts AL, Dodrill CL, Kosten TR.

Expert Opin Pharmacother. 2009 Aug;10(11):1727-40. doi: 10.1517/14656560903037168. Review.

Supplemental Content

Support Center